Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Current Leases (2019 - 2025)

Heron Therapeutics' Current Leases history spans 7 years, with the latest figure at $780000.0 for Q3 2025.

  • For Q3 2025, Current Leases fell 75.99% year-over-year to $780000.0; the TTM value through Sep 2025 reached $780000.0, down 75.99%, while the annual FY2024 figure was $3.0 million, 1.24% down from the prior year.
  • Current Leases reached $780000.0 in Q3 2025 per HRTX's latest filing, down from $1.5 million in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $3.3 million in Q3 2021 to a low of $780000.0 in Q3 2025.
  • Average Current Leases over 5 years is $2.7 million, with a median of $2.8 million recorded in 2023.
  • Peak YoY movement for Current Leases: rose 23.8% in 2024, then plummeted 75.99% in 2025.
  • A 5-year view of Current Leases shows it stood at $2.4 million in 2021, then grew by 11.46% to $2.7 million in 2022, then grew by 14.14% to $3.1 million in 2023, then fell by 1.24% to $3.0 million in 2024, then tumbled by 74.32% to $780000.0 in 2025.
  • Per Business Quant, the three most recent readings for HRTX's Current Leases are $780000.0 (Q3 2025), $1.5 million (Q2 2025), and $2.3 million (Q1 2025).